Jump to:
James Gould joined Ropes & Gray's corporate department in the Boston office in 2023. James graduated from Boston University School of Law in 2023 after attending College of the Holy Cross as an undergraduate.
During law school, James served as an editor on Boston University’s Journal of Science and Technology Law. As an undergraduate James studied chemistry and was named a Goldwater Scholar in 2019 for his research on self-assembled monolayers.
Experience
- Represented a biopharmaceutical company in an AI-enabled research collaboration worth up to $5.3 billion with a China-based pharmaceutical group to advance the discovery and development of novel oral drug candidates across multiple disease indications.
- Represented Blackstone Life Sciences in its collaboration with Takeda where funds managed by Blackstone Life Sciences will provide up to $300 million to co-fund certain Phase 3 trials for mezagitamab.
- Represented a multinational pharmaceutical company in a strategic transaction with a Chinese biotechnology company to develop potential first-in-class peptide therapeutics worth up to $3.5 billion.
- Represented Sanofi in acquisition of Dren Bio’s bispecific antibody-based program in immunology deal worth up to $1.9 billion.
- Represented Amylyx Pharmaceuticals, a global pharmaceutical company focused on developing treatments for neurodegenerative diseases, in its successful bid of more than $35.1 million to purchase the avexitide assets of Eiger BioPharmaceuticals, Inc. in the sale of Eiger’s assets pursuant to Section 363 of the bankruptcy code.
- Represented Regeneron in acquisition of 2seventy Bio platforms to create new R&D unit Regeneron Cell Medicines.